ArticleEuropean journal of nuclear medicine and molecular imaging2019
Improved specificity with
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 5 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer.Prostate cancer and prostatic diseases · 2025Pooled it
- Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.Annals of nuclear medicine · 2025Pooled it
- Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.European radiology · 2024Pooled it
- The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Pooled it
- Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Head-to-Head Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.Clinical & experimental metastasis · 2020Trial
- Beyond PSMA: The essential complementary role of MRI in staging prostate cancer with Low-PSMA expression phenotypes.European journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy of PSMA PET/CT radiomics analysis for risk stratification in newly diagnosed prostate cancer: a multicenter study.BMC medical imaging · 2025Article
- Risk of clinically significant prostate cancer undercategorized by multiparametric magnetic resonance imaging.Abdominal radiology (New York) · 2025Article
- Pathological and radiological features of false-positive lesions on [European journal of nuclear medicine and molecular imaging · 2025Article
- Development and validation of multivariable biopsy-free nomograms to predict clinically significant prostate cancer in patients with prostate-specific antigen levels ≥20 ng/mL.Translational andrology and urology · 2025Article
- The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.British journal of cancer · 2025Observational
- Diagnostic value ofCancer biology & therapy · 2024Article
- The value ofDiscover oncology · 2024Article
- PI-RADS-Based Segmented Threshold of PSMA-PET SUVmax Is Better than Traditional Fixed Threshold for Diagnosing Clinically Significant Prostate Cancer Especially for PI-RADS 3 Lesions.Molecular imaging and biology · 2023Article
- Article
- Up-to-Date Imaging and Diagnostic Techniques for Prostate Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
- A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.European urology open science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePositron emission tomography (PET) for prostate-specific membrane antigen (PSMA) represents a promising method for prostate cancer diagnosis and staging. Comparisons of PSMA-based tumour characterisation to multiparametric MRI (mpMRI) are limited, hence this study sought to compare the diagnostic accuracy of
methodsA retrospective cohort study of consecutive patients who underwent pre-operative mpMRI and
resultsFifty-eight patients (median age 65.5 years, median PSA 7.35 ng/mL) underwent RP, resulting in a high-risk cohort (≥pT3 69%). Sensitivities for identification of index lesion, bilateral and multifocal disease were 90%, 21%, 19% for mpMRI and 93%, 42%, 34% for
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.